Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA
Crossref DOI link: https://doi.org/10.1007/s12325-021-01627-8
Published Online: 2021-02-10
Published Print: 2021-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Li, Shuosha
Hu, Huabin
Ding, Dong
Zhu, Youwen
Huang, Jin http://orcid.org/0000-0002-8289-7071
Funding for this research was provided by:
Natural Science Foundation of Hunan Province (2018JJ3852)
Text and Data Mining valid from 2021-02-10
Version of Record valid from 2021-02-10
Article History
Received: 29 November 2020
Accepted: 15 January 2021
First Online: 10 February 2021